Tag Archives: Zyprexa

Alzheimer’s Therapy: Antipsychotics

Overview. Behavioral problems are prevalent in later stages of Alzheimer’s disease, when 50-60% of patients develop severe psychotic symptoms (). Behavioral symptoms range from depression and apathy to delusions, hallucinations, and aggressiveness. They are extremely distressing and burdensome to caregivers and affect both the quality of patient care and the choice of treatment. Aggressive and… Read More »

Information about Alzheimer’s Disease for Patients and Families

Alzheimer’s disease is the most common and well-known form of degenerative dementia. By definition, dementia is a syndrome, a cluster of symptoms, of impaired memory and cognition. Dementia is a cognitive disorder that impairs an individual’s memory and ability for reasoning, awareness, and judgment. Cognitive impairment in Alzheimer’s disease may involve disturbance of language (aphasia),… Read More »

Schizophrenia: Current Therapies

Etiology and Pathophysiology Schizophrenia has varied and ominous symptoms that generally begin in late adolescence or early adulthood and usually continue throughout life. The diagnostic criteria for schizophrenia have evolved over the past 20 years based on the different iterations of the Diagnostic and Statistical Manual of Mental Disorders and the International Classification of Diseases.… Read More »

Schizophrenia: Atypical Antipsychotics

Many atypical antipsychotics are available. In addition to those reviewed in the following sections, atypical agents include perospirone (Sumitomo’s Lullan) and zotepine (Fujisawa’s Lodopin, Aventis’s Nipolept, Orion Pharma’ s Zoleptil, generics). These drugs are not discussed in detail here because their mechanisms of action are similar to those of other atypical agents, they are launched… Read More »

Schizophrenia: Serotonin-Dopamine Antagonists

Serotonin-dopamine antagonists, together with dopamine partial agonists, are considered atypical antipsychotics. serotonin-dopamine antagonists have been used for the treatment of schizophrenia since the early 1990s, and currently marketed serotonin-dopamine antagonists include Novartis’s clozapine (Clozaril/Leponex, generics), Janssen’s risperidone (Risperdal), Eli Lilly’s olanzapine (Zyprexa), AstraZeneca’s quetiapine (Seroquel), and Pfizer’s ziprasidone (Geodon/Zeldox). TABLE . Emerging Therapies in Development… Read More »

Dissociative [Conversion] Disorders

Description of Medical Condition A sudden change in state of consciousness, identity, motor behavior, thoughts, feelings and perception of external reality to such an extent that these functions do not operate congruently. Many pathologic symptoms can be found, but the patient experiences dysphoria, suffering, and maladaptive functioning. Disorders include: • Dissociative amnesia • Dissociative fugue… Read More »

Delirium (Acute Confusional State)

Description of Medical Condition Delirium is a neurologic complication of illness and/or medication use that is especially common in older patients. The key diagnostic features are an acute change in mental status that fluctuates, abnormal attention, and either disorganized thinking or altered level of consciousness. Delirium is a medical emergency requiring immediate evaluation in order… Read More »

Changing Views of Schizophrenia and Antipsychotic Agents

In the years following the introduction of the first antipsychotic drugs (the mid-1950s), their most clinically salient effect was suppression of the symptoms of acute psychosis, including delusions, hallucinations, thought disorder, agitation, and gross disorganization. The past several years of research on the outcome of pharmacotherapy for schizophrenia have seen an emphasis on the domains… Read More »